Literature DB >> 11424973

The potential role of interleukin-2 in HIV.

R T Mitsuyasu1.   

Abstract

Interleukin-2 (IL-2) is a secretory cytokine produced by activated T cells that stimulates T cells, B cells, and natural killer cells to proliferate and release cytokines. In addition, IL-2 slows apoptosis of HIV-infected cells. Clinical studies have demonstrated that exogenous human recombinant IL-2 can be safely administered concurrently with potent antiretroviral therapy to HIV-infected patients. It was further demonstrated that recombinant human IL-2 therapy produces sustained increases in CD4+ cell number and function in patients with both early and late HIV disease. Further evaluation of the clinical efficacy of IL-2 in HIV-infected patients is expected to provide important information on the utility of recombinant human IL-2 in HIV disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11424973     DOI: 10.1097/00002030-200102002-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  6 in total

Review 1.  Prospects for immune reconstitution in HIV-1 infection.

Authors:  N Imami; F Gotch
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 2.  Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Authors:  Stella J Berendam; Ashley N Nelson; Ria Goswami; Deborah Persaud; Nancy L Haigwood; Ann Chahroudi; Genevieve G Fouda; Sallie R Permar
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

3.  Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity.

Authors:  Chun-ping Wan; Li-xin Gao; Li-fei Hou; Xiao-qian Yang; Pei-lan He; Yi-fu Yang; Wei Tang; Jian-min Yue; Jia Li; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2013-03-25       Impact factor: 6.150

4.  Interleukin-2 enhances the cytotoxic activity of circulating natural killer cells in patients with chronic heart failure.

Authors:  Heng-Chen Yao; Shu-Qin Liu; Ke Yu; Min Zhou; Le-Xin Wang
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

5.  Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2.

Authors:  Jakob Michaëlsson; Brian R Long; Christopher P Loo; Lewis L Lanier; Gerald Spotts; Frederick M Hecht; Douglas F Nixon
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

6.  Brain 18F-FDG PET of SIV-infected macaques after treatment interruption or initiation.

Authors:  William Schreiber-Stainthorp; Sanhita Sinharay; Sharat Srinivasula; Swati Shah; Jing Wang; Lori Dodd; H Clifford Lane; Michele Di Mascio; Dima A Hammoud
Journal:  J Neuroinflammation       Date:  2018-07-14       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.